Search fresh public links, source activity, and ready-to-use post angles for Antibody-Drug Conjugates.
Fresh curated links around Antibody-drug conjugates are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how were they discovered? Learn about the history of ADCs, the...
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New research has helped to revolutionize the drug class and de...
The team’s strategy—called antibody–ADC click—relies on the rapid ligation between trans‑cyclooctene (TCO) and tetrazine moieties. The post Modular Antibody–ADC Click Chemistry Ove...
Roche’s Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) designed for the growing pool of patients who progress after treatment with...
This collection of articles and expert perspectives explores the critical challenges shaping ADC development today, from analytical strategy and impurity control to linker technolo...
Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and...
The concept of targeted therapeutics is often traced back to German Nobel laureate Paul Ehrlich’s “magic bullet” in 1907, which envisioned a single entity that could both recognize...
In this GEN webinar, our expert speaker, Cindy Cheng, PhD, will explore how mechanism-driven payload pairing counters specific resistance pathways by combining orthogonal or comple...
Lonza, through one of its affiliated companies, is eligible to receive upfront, clinical, regulatory, and commercial milestone payments, plus royalties on the net sales of resultin...
Hansoh Pharmaceutical has guided its GSK-partnered, B7-H3-directed antibody-drug conjugate to another phase 3 win in China.
Strategic licensing agreement enables ZoeNCure to build a high-potency, ADC pipeline targeting severe gastrointestinal and liver cancers in India.
There are lots of different B cell depleting antibodies used in cancer and autoimmunity. There are three approved for MS (in blue below. Ublituximab, ocrelizumab and ofatumumab), b...
A shape-changing drug attacks tumors in several ways and improves outcomes in mice. A tumor is rarely made up of identical cells. As cancer progresses or adapts to treatment, diffe...
Chimeric antigen receptor (CAR) therapy is away you harness the specificity potential of antibodies and the killing potential of T cells. You make T cells to express bits of an ant...
With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.
GSK gained rights to a Hutchmed antibody-targeted therapy conjugate, or ATTC. This new type of targeted therapy blocks two cancer-driving proteins and will initially be developed f...
AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates and progression-free survival in patients with relapsed/...
The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for fro...
Preclinical study found that fusing immunoglobulin G (IgG) antibodies to albumin minimized antibody transport across the placenta and prevented adverse effects in offspring in mice...
Cancer researchers have reported a new strategy that combines bacterial tumor targeting, nutrient deprivation and immune stimulation in a single therapeutic design. The approach us...
To produce stable cell lines for monoclonal antibody production, manufacturers typically use the piggyBac transposon system. For larger, multi-specific antibodies that have payload...
Follow-on investment led by the HNI (High-Net-Worth Individual) Tyagi Family bringing total capital raised to date to INR 22.5 Crore, underscoring strong investor confidence in Zoe...
Pathos AI struck a deal for rights to a bispecific antibody drug conjugate from Alphamab that could become first in a new class of cancer drugs. Separately, the startup began a par...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.